Also trades as: TVGN (NASDAQ) · $vol 0M
TVGNW NASDAQ
Tevogen Bio Holdings Inc.
1W: +19.0%
1M: +15.4%
3M: -1.4%
YTD: -1.4%
1Y: -27.3%
$0.04
-0.00 (-3.05%)
Weekly Expected Move ±11.7%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.6M
52W Range0.0331-0.045
Volume27,236
Avg Volume107,180
Beta0.10
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORyan H. Saadi
Employees18
SectorHealthcare
IndustryBiotechnology
IPO Date2024-02-15
Websitetevogen.com
15 Independence Blvd
Warren, NJ 07059
US
Warren, NJ 07059
US
877 838 6436
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Latest News
Tevogen Bio (NASDAQ:TVGN) Shares Down 5.9% – Here’s What Happened
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen Bio (NASDAQ:TVGN) Sets New 52-Week Low – Should You Sell?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Saadi Ryan H. | G-Gift | 50,000 | — | 2025-12-18 |
| Desai Kirti | G-Gift | 300,000 | — | 2025-12-11 |
| Saadi Ryan H. | G-Gift | 460,000 | — | 2025-12-11 |
| Saadi Ryan H. | G-Gift | 20,000 | — | 2025-08-15 |
| Saadi Ryan H. | A-Award | 8,000,000 | — | 2025-06-27 |